Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial

Itamar Raz, György Jermendy, Peter W.F. Wilson, Barbara N. Campaigne, Krzysztof Strojek, Lisa Kerr, Irina Kowalska, Zvonko Milicevic, Velimir Bozikov, Scott J. Jacober, Anselm K. Gitt

Research output: Article

260 Citations (Scopus)

Abstract

OBJECTIVE - Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS - Patients (type 2 diabetes, aged 30-75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmo1/1) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/1). RESULTS - total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1-1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174,31.2%) and BASAL(n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8-1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 ±0.1 vs. 7.8 ± 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmo1/1; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmo1/1; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmo1/1; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmo1/1; P = 0.233) versus the PRANDIAL group. CONCLUSIONS - Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.

Original languageEnglish
Pages (from-to)381-386
Number of pages6
JournalDiabetes care
Volume32
Issue number3
DOIs
Publication statusPublished - márc. 2009

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Fingerprint Dive into the research topics of 'Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial'. Together they form a unique fingerprint.

  • Cite this

    Raz, I., Jermendy, G., Wilson, P. W. F., Campaigne, B. N., Strojek, K., Kerr, L., Kowalska, I., Milicevic, Z., Bozikov, V., Jacober, S. J., & Gitt, A. K. (2009). Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabetes care, 32(3), 381-386. https://doi.org/10.2337/dc08-1671